PROTAC HK2 Degrader-1

PROTAC HK2 Degrader-1 是一种靶向 Hexokinase 2 (HK2) 的 PROTAC,由 Hexokinase 2 (HK2) 抑制剂 Lonidamine (MS-N14681) 与 CRBN 配体 Thalidomide (MS-B42308) 组成,通过泛素-蛋白酶体系统形成三元复合体降解 Hexokinase 2 (HK2) 蛋白,诱导线粒体损伤并引发细胞焦亡 (pyroptosis),能有效抑制乳腺肿瘤生长并减少 Cisplatin (MS-E94993) 的结肠副作用,可用于乳腺癌的研究(粉色:Hexokinase 2 配体 (MS-N14681);蓝色:Cereblon 配体 (MS-N78428);黑色:连接子 (MS-Y19507))。
产品编号: MS-B27609 纯度: 99.76% CAS No.: 3033812-84-6 分子式: C32H28Cl2N6O5 分子量: 647.51
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

PROTAC HK2 Degrader-1 是一种靶向 Hexokinase 2 (HK2) 的 PROTAC,由 Hexokinase 2 (HK2) 抑制剂 Lonidamine (MS-N14681) 与 CRBN 配体 Thalidomide (MS-B42308) 组成,通过泛素-蛋白酶体系统形成三元复合体降解 Hexokinase 2 (HK2) 蛋白,诱导线粒体损伤并引发细胞焦亡 (pyroptosis),能有效抑制乳腺肿瘤生长并减少 Cisplatin (MS-E94993) 的结肠副作用,可用于乳腺癌的研究(粉色:Hexokinase 2 配体 (MS-N14681);蓝色:Cereblon 配体 (MS-N78428);黑色:连接子 (MS-Y19507))。

生物实验数据

生物活性 PROTAC HK2 Degrader-1 is a PROTAC targeting Hexokinase 2 (HK2), composed of the Hexokinase 2 (HK2) inhibitor Lonidamine (MS-N14681) and the CRBN ligand Thalidomide (MS-B42308), which forms a ternary complex via the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein, inducing mitochondrial damage and triggering pyroptosis, effectively inhibiting breast tumor growth and reducing the colonic side effects of Cisplatin (MS-E94993), and can be used for breast cancer research (pink: Hexokinase 2 ligand (MS-N14681); blue: Cereblon ligand (MS-N78428); black: linker (MS-Y19507)).
IC50 & Target

DC50: 2.56 μM (Hexokinase 2, HK2 in 4T1); 0.79 μM ((Hexokinase 2, HK2 in MDA-MB-231)

体外研究
(In Vitro)

PROTAC HK2 Degrader-1 抑制 786-O,4T1,PANC-1,HGC-27,MCF-1 细胞增殖的 IC50 分别为 34.07 μM,5.08 μM,31.53 μM,6.11 μM,21.65 μM。
PROTAC HK2 Degrader-1 对 HK2 的 DC50 为2.56 μM (4T1) 和 0.79 μM (MDA-MB-231)。
PROTAC HK2 Degrader-1 (0.01-200 μM, 36 h) 选择性地抑制乳腺癌细胞增殖,并通过泛素介导的蛋白酶体途径,以时间和浓度依赖的方式刺激 HK2 蛋白的降解。
PROTAC HK2 Degrader-1 (10 μM for 4T1, 0.5 μM for MDA-MB-231, 24 h) 通过泛素-蛋白酶体系统形成一个三元复合体降解HK2蛋白。
PROTAC HK2 Degrader-1 (20 μM, 36 h) 降解 HK2 导致线粒体损伤后释放细胞色素 C 激活 caspase-3,裂解 GSDME 引发热昏迷从而细胞释放危险信号,如 ATP、HMGB1、CRT 等,最后导致诱发细胞免疫死亡。
PROTAC HK2 Degrader-1 (20 μM, 36 h) 能诱导 PD-L1 蛋白从细胞膜内化到细胞质,并减少 PD-L1 蛋白的总量。

Cell Cytotoxicity Assay

Cell Line: 4T1, MDA-MB-231, PUMC-HUVEC-T1
Concentration: 20 μM
Incubation Time: 72 h (MTT), 48 h (CCK-8)
Result: Showed the greatest impact on 4T1 and HGC-27 cells, with IC50 dosages of 5.08 and 6.11 μM.
Selectively suppressed breast cancer cell proliferation and stimulates HK2 protein degradation.
Prevented 4T1 cells to form a colony and had little influence on HUVECT-1.

Western Blot Analysis

Cell Line: 4T1, MDAMB-231
Concentration: 20 μM; 0.01, 0.05, 0.1, 0.5, 1.0, 2.0, 5.0, 10, 20, 50, 100, 150, 200 μM; 10 μM; 0.5 μM.
Incubation Time: 36 h; 24 h
Result: Degraded 71.06% of HK2 at 20 μM in 4T1 and MDAMB-231 cells.
DC50=2.56 μM (4T1) and 0.79 μM (MDA-MB-231), respectivley.
Promoted the degradation of HK2 protein within 12 h, with the greatest degradation impact at 36 h in 4T1 cells and MDA-MB-231 cells.
Degradation capacity was reduced, because pretreatment with Tha and LND occupy the protein pocket and disrupt the formation of the ternary complex of HK2, CRBN and C-02.
Increased the expression of VDAC and Bax and decreased the level of Bcl-2 protein.
had lower levels of full-length caspase-3 and higher levels of cleaved caspase-3.
Cleaved GSDME through cleaved caspase-3, increasing the N-terminus of GSDME protein and thus triggering pyroptosis in 4T1 cells.

Immunofluorescence

Cell Line: 4T1 and MDA-MB-231
Concentration: 20 μM
Incubation Time: 36 h
Result: Caused the degradation of HK2 protein in a concentration dependent manner.
Significantly reduced the visual yellow fluorescence of HK2 protein.
体内研究
(In Vivo)

PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mice) 需要提及造模动物是什么~)抑制4T1肿瘤模型的肿瘤生长。
PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mice) 能诱导GSDME依赖性的热化反应,实现肿瘤免疫反应,有效抑制乳腺肿瘤的生长。
PROTAC HK2 Degrader-1 (Cisplatin (MS-E94993) 10mg/kg, i.v., C-02 50mg/kg, i.p., 25 days, six-weekold female BALB/c mice) 可以使顺铂增敏,同时减少顺铂的结肠副作用,具有潜在的临床价值。

Animal Model: xenograft models, into six-weekold female BALB/c mice
Dosage: 50 mg/kg
Administration: Intraperitoneal injection, bid, for nine times.
Result: Reduced proliferation and damaged nuclei in mouse models.
Increased the levels of Cytokines IL-1β, IFN-γ, and TNF-α significantly and decreased the level of TGF-β and IL-10.
Elevated levels of cleaved-Casp-3 and GSDME-N in tumor tissues of mouse.
Animal Model: breast tumor model in mice by injecting 4T1 cells subcutaneously into six-weekold female BALB/c mice
Dosage: Cisplatin (MS-E94993) 10mg/kg, 50mg/kg
Administration: Cisplatin (MS-E94993) (10mg/kg, i.v.), 50mg/kg, i.p., 25 days
Result: Inhibited tumor growth and tumor volume.
Decreased HK2 protein level, while co- treated with Cisplatin (MS-E94993).
Could alleviate Cisplatin (MS-E94993) aggravated colon damage.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 647.51
分子式 C32H28Cl2N6O5
CAS No. 3033812-84-6

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (154.44 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.5444 mL7.7219 mL15.4438 mL38.6094 mL
5 mM0.3089 mL1.5444 mL3.0888 mL7.7219 mL
10 mM0.1544 mL0.7722 mL1.5444 mL3.8609 mL
15 mM0.1030 mL0.5148 mL1.0296 mL2.5740 mL
20 mM0.0772 mL0.3861 mL0.7722 mL1.9305 mL
25 mM0.0618 mL0.3089 mL0.6178 mL1.5444 mL
30 mM0.0515 mL0.2574 mL0.5148 mL1.2870 mL
40 mM0.0386 mL0.1930 mL0.3861 mL0.9652 mL
50 mM0.0309 mL0.1544 mL0.3089 mL0.7722 mL
60 mM0.0257 mL0.1287 mL0.2574 mL0.6435 mL
80 mM0.0193 mL0.0965 mL0.1930 mL0.4826 mL
100 mM0.0154 mL0.0772 mL0.1544 mL0.3861 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础